Prevacid is a brand name of lansoprazole, approved by the FDA in the following formulation(s):
PREVACID (lansoprazole - capsule, delayed rel pellets; oral)
Manufacturer: TAKEDA PHARMS NA
Approval date: May 10, 1995
Strength(s): 15MG [AB], 30MG [RLD][AB]
PREVACID (lansoprazole - tablet, delayed release, orally disintegrating; oral)
Manufacturer: TAKEDA PHARMS NA
Approval date: August 30, 2002
Strength(s): 15MG [AB], 30MG [RLD][AB]
Has a generic version of Prevacid been approved?
A generic version of Prevacid has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Prevacid and have been approved by the FDA:
lansoprazole capsule, delayed rel pellets; oral
Manufacturer: DR REDDYS LABS LTD
Approval date: October 15, 2010
Strength(s): 15MG [AB], 30MG [AB]
Manufacturer: MATRIX LABS LTD
Approval date: November 10, 2009
Strength(s): 15MG [AB], 30MG [AB]
Manufacturer: SANDOZ
Approval date: April 23, 2010
Strength(s): 15MG [AB], 30MG [AB]
Manufacturer: TEVA PHARMS
Approval date: November 10, 2009
Strength(s): 15MG [AB], 30MG [AB]
lansoprazole tablet, delayed release, orally disintegrating; oral
Manufacturer: TEVA PHARMS
Approval date: October 15, 2010
Strength(s): 15MG [AB], 30MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prevacid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Rapidly disintegratable multiparticular tablet
Patent 5,464,632
Issued: November 7, 1995
Inventor(s): Cousin; Gerard & Bruna; Etienne & Gendrot; Edouard
Assignee(s): Laboratoires Prographarm
Rapidly disintegratable multiparticulate tablet the excipient mixture of which is suitable for imparting a disintegration rate such that the tablet disintegrates in the mouth in an extremely short time, notably in less than sixty seconds, characterized by the fact that the active substance is present in the form of coated microcrystals or coated or uncoated microgranules.Patent expiration dates:
- November 7, 2012
- May 7, 2013✓
- November 7, 2012
Orally disintegrable tablets
Patent 6,328,994
Issued: December 11, 2001
Inventor(s): Shimizu; Toshihiro & Morimoto; Shuji & Tabata; Tetsuro
Assignee(s): Takeda Chemical Industries, Ltd.
An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 .mu.m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.Patent expiration dates:
- May 17, 2019
- November 17, 2019✓
- May 17, 2019
Rapidly Disintegrable solid preparation
Patent 7,399,485
Issued: July 15, 2008
Inventor(s): Shimizu; Toshihiro & Sugaya; Masae & Nakano; Yoshinori
Assignee(s): Takeda Pharmaceutical Company Limited
A rapidly disintegrable solid preparation which comprises (i) a pharmacologically active ingredient, (ii) a sugar and (iii) a low-substituted hydroxypropylcellulose having 5% by weight or more to less than 7% by weight of hydroxypropoxyl group. The rapidly disintegrable solid preparation has fast disintegrability, suitable strength and no roughness.Patent expiration dates:
- May 26, 2018✓
- November 26, 2018✓
- May 26, 2018
Orally disintegrable tablets
Patent 7,431,942
Issued: October 7, 2008
Inventor(s): Shimizu; Toshihiro & Morimoto; Shuji & Tabata; Tetsuro
Assignee(s): Takeda Pharmaceutical Company Limited
An orally disintegrable tablet of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.Patent expiration dates:
- May 17, 2019✓
- November 17, 2019✓
- May 17, 2019
Orally disintegrable tablets
Patent 7,875,292
Issued: January 25, 2011
Inventor(s): Shimizu; Toshihiro & Morimoto; Shuji & Tabata; Tetsuro
Assignee(s): Takeda Pharmaceutical Company Limited
An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.Patent expiration dates:
- May 17, 2019✓
- November 17, 2019✓
- May 17, 2019
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 28, 2011 - INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
- April 28, 2012 - PEDIATRIC EXCLUSIVITY
See also...
- Prevacid Consumer Information (Drugs.com)
- Prevacid Delayed-Release Capsules Consumer Information (Wolters Kluwer)
- Prevacid Powder Packet Consumer Information (Wolters Kluwer)
- Prevacid Consumer Information (Cerner Multum)
- Prevacid Advanced Consumer Information (Micromedex)
- Lansoprazole Consumer Information (Drugs.com)
- Lansoprazole Consumer Information (Wolters Kluwer)
- Lansoprazole Delayed-Release Capsules Consumer Information (Wolters Kluwer)
- Lansoprazole Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
- Lansoprazole Powder Packet Consumer Information (Wolters Kluwer)
- Lansoprazole Consumer Information (Cerner Multum)
- Lansoprazole Advanced Consumer Information (Micromedex)
- Lansoprazole AHFS DI Monographs (ASHP)
No comments:
Post a Comment